This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
A new report from Dr. Michael Worobey alleges that it is likely that COVID-19 originated from a raccoon dog at the Wuhan live animal market in China. While his report does not rule out the coronavirus could have escaped from a lab, Worobey's evidence points to a natural origin.
Jill and Carlo are back to cover the latest in the Rittenhouse trial, new information on the origins of Covid, return-to-office and more.
JOIN US FOR THE YOUTUBE WATCH PARTY @ 9aET: http://www.youtube.com/cheddarnow
Over the weekend, Russia fired a missile at one of its own satellites, triggering an explosion that launched thousands of pieces of shrapnel through space and forced the astronauts aboard the International Space Station to shelter in place. Senior Writer from Space.com Chelsea 'Foxanne' Gohd, joined Cheddar to discuss more.
Gerald Comissiong, CEO of Todos Medical, joins None of the Above to discuss why we're seeing surges of COVID-19 cases in Europe, the potential for a winter surge of COVID-19, the benefits of high vaccination rates in a community, and the coming COVID treatment pills.
Cognitive healthcare platform BrainCheck recently raised $10 million in a Series B round. The platform offers neurologists a new way to detect and care for brain disorders like Alzeheimer's, and brain injuries like concussions. BrainCheck CEO Yael Katz joined Cheddar News' Closing Bell to discuss.
On this episode of Cheddar Innovates: Ice Barrel CEO breaks down the physical and mental health benefits to cold therapy training; Dishcraft CEO explains how its robotics is transforming the role of a dishwasher in restaurant kitchens; A look at Curiosity Stream's original series 'The Year That Rocked The World.'
Jill Wagner is joined by Baker to talk about kids and vaccines: we finally know how many young kids are getting vaccinated. Plus, Democrats are working on a Plan B for paid family leave. And the salad chain Sweetgreen goes public.
A breakthrough deal between the U.S. and China when it comes to climate has finally been reached. The two countries have pledged to work together to curb carbon emissions. Amy Harder, executive editor at Cipher, joined Cheddar News to discuss more.
Joey Roulette, space reporter for The New York Times, joined Cheddar to break down the intense backlash Russia is seeing after its missile test sent destroyed a non-functioning satellite and sent thousands of pieces of debris potentially at the ISS, endangering astronauts onboard. He said while the blast happened days ago, there is still some risk to the station as the space junk threat remains. So far, the U.S., NATO, and the European Union have condemned Russia for the test.
Jill is joined by “Friend of the Pod” Mosheh Oinounou to talk booster shots, and whether “fully vaccinated” will eventually mean three shots, not two. Plus, the latest on the Kyle Rittenhouse trial. And the research is in: we know now the perfect way to hug. Also, Jill and Mosheh debate whether Airpods are passé.
